Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses
Koup RA, et al.Optimal Ag targeting and activation of APCs, especially dendritic cells (DCs), are important in vaccine development. In this study, they report the effects of different Toll-like receptor (TLR)-binding compounds to enhance immune responses induced by human APCs, including CD123+ plasmacytoid DCs (PDCs), CD11c+ myeloid DCs (MDCs), monocytes, and B cells. Together, the data show that targeting specific DC subsets using TLR ligands can enhance their ability to activate virus-specific T cells, providing information for the rational design of TLR ligands as adjuvants for vaccines or immune modulating therapy.
Journal of Immunology
2003, 171: 4320-4328
—Posted: November 11, 2003
More journal headlines: This month | Last month | Search archive